1. Home
  2. CBIO vs KINS Comparison

CBIO vs KINS Comparison

Compare CBIO & KINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$10.94

Market Cap

198.9M

Sector

N/A

ML Signal

HOLD

KINS

Kingstone Companies Inc.

HOLD

Current Price

$17.33

Market Cap

209.0M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBIO
KINS
Founded
2003
1886
Country
United States
United States
Employees
N/A
N/A
Industry
Property-Casualty Insurers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
198.9M
209.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CBIO
KINS
Price
$10.94
$17.33
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$25.60
N/A
AVG Volume (30 Days)
105.4K
136.2K
Earning Date
02-23-2026
02-23-2026
Dividend Yield
N/A
1.16%
EPS Growth
N/A
69.11
EPS
N/A
2.26
Revenue
N/A
$198,583,138.00
Revenue This Year
N/A
$37.94
Revenue Next Year
N/A
$8.63
P/E Ratio
N/A
$7.65
Revenue Growth
N/A
32.70
52 Week Low
$9.81
$13.08
52 Week High
$21.40
$22.40

Technical Indicators

Market Signals
Indicator
CBIO
KINS
Relative Strength Index (RSI) 33.72 64.89
Support Level $10.86 $15.89
Resistance Level $11.68 $16.97
Average True Range (ATR) 0.76 0.57
MACD -0.16 -0.05
Stochastic Oscillator 11.67 70.50

Price Performance

Historical Comparison
CBIO
KINS

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

About KINS Kingstone Companies Inc.

Kingstone Companies Inc is a multi-line regional property and casualty insurance holding company. It offers insurance policies to small and mid-sized businesses as well as to individuals.

Share on Social Networks: